75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
Finanznachrichten1h
DelveInsight Business Research, LLP: 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...
Seeking Alpha5h
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...